SOX8 (SRY-Box Transcription Factor 8)

High SOX8 expression promotes EnzR in PCa, suggesting SOX8 as a potential therapeutic target. Our findings demonstrate that SOX8 drives EnzR by activating the SOX8/CPT2 axis, thereby inducing lipid metabolic reprogramming in PCa cells.

In conclusions, SOX8 functions as a molecular hub linking KRAS and TGF-β pathways, promoting epithelial-mesenchymal transition (EMT), invasive capacity, and chemotherapy resistance. This novel KRAS-SOX8-TGF-β axis plays the important role in invasion and metastasis of pancreatic cancer, suggesting SOX8 as a useful prognostic biomarker and therapeutic target.

Moreover, it demonstrated the significant role of SOX8 in HCC progression and LNM, which appears to modulate the malignant phenotype of HCC cells, encompassing enhanced proliferation, stem cell-like properties, and invasive migration through the induction of EMT. These collective findings implicate SOX8 as a promising candidate for targeted therapeutic intervention in HCC.

The ASIC1-SOX8 axis emerges as a dual prognostic biomarker and molecular subtype regulator in LGG, linking acidic microenvironments to immune evasion and IDH-driven glioma classification. Its clinical relevance in stratifying low-grade, IDH-mutant tumors highlights therapeutic potential for microenvironment-targeted immunotherapy.

Our study reveals a novel EHMT1-SOX8 axis that mediates metastasis in ERMS.

Conversely, dysbiosis or the presence of pathogenic bacteria (Ruminococcus) associated with the SOX8 gene could lead to chemoresistance, altered metabolic pathways, and increased toxicity. These findings underscore the potential implications for treatment outcomes and personalized medicine.

The SOX gene family is closely implicated in the onset and progression of lung adenocarcinoma, of which most members may be used as prognostic marker genes for patients.

The new compound C4 shows  better ability to degrade eEF2K and stronger anti-cancer activity than C1. These findings not only uncover the pivotal role of the eEF2K/AURKA/SOX8 axis in TNBC progression, but also provide a promising lead compound for developing novel drug for treatment of TNBC.

For instance, genetic variants of SOX8 have been linked to multiple sclerosis and familial essential tremor, while SOX8 alterations have been related to poor cancer prognosis and infertility. This Review provides an overview of Sox8's versatile role in development and adult tissues as well as its lesser-known contributions to various diseases, and its potential as a therapeutic target.

All variants increased SOX9-mediated reporter activation independently of protein stabilization, suggesting that CPD may also modulate SOX9's transactivation function. Altogether, these findings concur that CPD has critical functions, that SOX9 decisively controls odontogenesis, and that gain-of-function variants may markedly perturb both this process and skeletogenesis.

In translational medicine, we found that blocking LGALS3 improved the therapeutic sensitivity of HDAC inhibitors. Our findings revealed the role of the novel HDAC7-H3K27ac-SOX8/JUN-LGALS3-ITGB1 axis in maintaining the crosstalk between MES GBM and M2 MDM, highlighting that HDAC7 and LGALS3 may serve as potential prognostic biomarkers and therapeutic targets in GBM.

Next-generation sequencing revealed multiple differential features between SF- MPNST, D-MPNST, SCM, and DM, including tumor mutation burden, mutational signatures, and differentially expressed genes. These findings help advance our understanding of disease pathogenesis and improve diagnostic modalities.